about
The dopamine theory of addiction: 40 years of highs and lowsThe Center for Integrated Molecular Brain Imaging (Cimbi) databaseNeural correlates of the psychedelic state as determined by fMRI studies with psilocybinSerotonin transporter binding in the hypothalamus correlates negatively with tonic heat pain ratings in healthy subjects: a [11C]DASB PET studyEndogenous plasma estradiol in healthy men is positively correlated with cerebral cortical serotonin 2A receptor bindingA nonlinear relationship between cerebral serotonin transporter and 5-HT(2A) receptor binding: an in vivo molecular imaging study in humansSeasonal changes in brain serotonin transporter binding in short serotonin transporter linked polymorphic region-allele carriers but not in long-allele homozygotesThe personality trait openness is related to cerebral 5-HTT levelsPsilocybin with psychological support for treatment-resistant depression: an open-label feasibility studyCortical and Subcortical 5-HT2A Receptor Binding in Neuroleptic-Naive First-Episode Schizophrenic PatientsDecreased Frontal Serotonin2A Receptor Binding in Antipsychotic-Naive Patients With First-Episode SchizophreniaSerotonergic neurotransmission in emotional processing: New evidence from long-term recreational poly-drug ecstasy useIn vivo imaging of cerebral dopamine D3 receptors in alcoholism.Endogenous opioid release in the human brain reward system induced by acute amphetamine administration.The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories.Cerebral 5-HT2A receptor and serotonin transporter binding in humans are not affected by the val66met BDNF polymorphism status or blood BDNF levels.The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level-Dependent Resting State Functional Connectivity.Familial risk for mood disorder and the personality risk factor, neuroticism, interact in their association with frontolimbic serotonin 2A receptor binding.Brain serotonin 2A receptor binding: relations to body mass index, tobacco and alcohol use.Positron emission tomography and single photon emission CT molecular imaging in schizophrenia.The brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)C]Ro15-4513 positron emission tomography study.Serotonin 2A receptors, citalopram and tryptophan-depletion: a multimodal imaging study of their interactions during response inhibition.Blunted Endogenous Opioid Release Following an Oral Amphetamine Challenge in Pathological GamblersFunctional connectivity measures after psilocybin inform a novel hypothesis of early psychosis.Altered Insula Connectivity under MDMA.The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description.Decreased hippocampal translocator protein (18 kDa) expression in alcohol dependence: a [11C]PBR28 PET studyBrain imaging of serotonin 4 receptors in humans with [11C]SB207145-PET.A probabilistic approach to delineating functional brain regions.Neural substrates of cue reactivity and craving in gambling disorder.Cerebral serotonin transporter binding is inversely related to body mass index.High familial risk for mood disorder is associated with low dorsolateral prefrontal cortex serotonin transporter binding.Amphetamine induced endogenous opioid release in the human brain detected with [¹¹C]carfentanil PET: replication in an independent cohort.In vivo vulnerability to competition by endogenous dopamine: comparison of the D2 receptor agonist radiotracer (-)-N-[11C]propyl-norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]-raclopride.A PET imaging agent with fast kinetics: synthesis and in vivo evaluation of the serotonin transporter ligand [11C]2-[2-dimethylaminomethylphenylthio)]-5-fluorophenylamine ([11C]AFA).Prefrontal serotonin transporter availability is positively associated with the cortisol awakening response.The new PET imaging agent [11C]AFE is a selective serotonin transporter ligand with fast brain uptake kinetics.Gender and the use of hormonal contraception in women are not associated with cerebral cortical 5-HT 2A receptor binding.Evidence for GABA-A receptor dysregulation in gambling disorder: correlation with impulsivity.Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
P50
Q22251015-7C2F57B4-2921-47C1-8F70-23A95E984ED4Q22329404-7cf050e5-461d-1cd1-b701-ad7b73c110cbQ24633222-DE97CF90-E2BB-4558-9372-568756525DE6Q26720217-1ef4e1dc-4300-1124-7d50-fc9ad81f692dQ27114804-85208304-4b45-e86b-578a-62074787c367Q27114974-89bb8534-49fc-0328-8340-1da7303d9c95Q27115017-475103a4-45d0-bbc4-58bc-6558f000f9edQ27115023-6f75070d-47d7-d74c-1f50-ad523e45dd2eQ28005551-DE21A61A-31E1-4C80-8332-47CBEB45B216Q29364500-AE625139-076C-4101-9735-77827D5D7FECQ29364524-32931D0E-3D73-427C-8E61-53832A99DFA1Q29473848-32681F39-2AAD-4A98-95D1-F9A6B7AEB240Q33620597-676738D2-6023-4579-BEE9-813C5DBC7B82Q34258315-85002166-F278-4F23-BCDD-72213F8AF6B3Q34392399-4B38ECCC-0BE9-49A2-AE84-51156D0637E4Q34505000-64814040-A0EB-4601-872A-AEB27E761914Q34659485-1636DE3C-99D2-4582-A158-2B3C4B2AD293Q34660833-754C200F-EDB7-43CE-8EB6-81927FC96585Q34982103-7D219574-3304-4C1C-B569-9F9DAFD33ABAQ35692963-CBD94121-0B44-4F4B-AEA2-4E81CACBA73BQ35811094-FDCF86F2-1754-4AB1-B04D-45EE6A4F086DQ36775232-A216F1A6-7586-45E1-BC98-00EF977E0A1AQ36906636-74298C71-21BB-4697-8B9B-988C3E628C7DQ37228293-38E3FF5C-98FD-4245-9E87-9FF39097C896Q38962662-4B69E20B-6AD5-4936-8789-A554A3FF3B05Q38977208-9EBE9FC2-C850-499D-8D44-35FD26D49DC0Q39029440-743B87A9-D356-48A4-8C64-6408A29102F9Q39907303-2F3E612A-5737-45F3-A259-243A4C141C42Q39979117-666BEF15-5D37-47C4-972A-AB6BADE7FE71Q41271258-D22B24F7-6CE3-423D-AEE2-A3C4D29F2B58Q43103856-813B329F-AEB0-4389-9391-742B62BEA11AQ44058654-AC08FFE8-C586-4CAC-BB5D-C524F8BB475DQ44344726-654EDF92-FBFF-45C0-8C13-2CA5B747D5B0Q44830953-4123C086-A7CB-45AB-9CBB-F4E0525E4580Q44972351-E9326845-5D5B-40B5-BC89-EEBE0F98CEFBQ45001609-43D6F753-9FB7-4805-8FDF-5CBAFF8DA75AQ45193028-166CAC44-5CF5-4CC8-904C-8350DC314561Q45950272-7F5EAB31-6DAA-415D-A03B-847176CECAC5Q47136943-7EDF1FF1-6C21-4625-9FBB-92BAAF9767E9Q47577495-2DE39EB3-323B-414D-8E29-9D0819D562E4
P50
description
dansk forsker og læge
@da
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
David Erritzøe
@ast
David Erritzøe
@da
David Erritzøe
@de
David Erritzøe
@en
David Erritzøe
@es
David Erritzøe
@fo
David Erritzøe
@fr
David Erritzøe
@is
David Erritzøe
@kl
David Erritzøe
@nb
type
label
David Erritzøe
@ast
David Erritzøe
@da
David Erritzøe
@de
David Erritzøe
@en
David Erritzøe
@es
David Erritzøe
@fo
David Erritzøe
@fr
David Erritzøe
@is
David Erritzøe
@kl
David Erritzøe
@nb
altLabel
D Erritzoe
@da
D Erritzoe
@de
D Erritzoe
@en
D. Erritzoe
@da
D. Erritzoe
@de
D. Erritzoe
@en
David Erritzoe
@da
David Erritzoe
@de
David Erritzoe
@en
David Erritzoe
@fo
prefLabel
David Erritzøe
@ast
David Erritzøe
@da
David Erritzøe
@de
David Erritzøe
@en
David Erritzøe
@es
David Erritzøe
@fo
David Erritzøe
@fr
David Erritzøe
@is
David Erritzøe
@kl
David Erritzøe
@nb
P106
P21
P31
P496
0000-0002-7022-6211